GO:0038193 thromboxane A2 signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038193 (thromboxane A2 signaling pathway) is a biological process defined as a G protein-coupled receptor signaling pathway initiated by thromboxane A2 binding to its receptor on the surface of a target cell, and ending with regulation of a downstream cellular process such as transcription.
• Thromboxane A2 (TXA2) is a labile arachidonic acid metabolite synthesized by thromboxane synthase and acting through the TP receptor, a G protein-coupled receptor encoded by TBXA2R.
• The pathway is best known for platelet activation, aggregation and secretion, and it is a central node in hemostasis and thrombosis.
• Beyond platelets, TXA2 signaling regulates vascular tone, endothelial insulin signaling, immune surveillance and tumor progression.
• Aspirin and other COX inhibitors suppress TXA2 synthesis, and recent work shows that platelet TXA2 suppresses T cell immunity to limit metastasis, linking this pathway to cancer immunotherapy.
• The pathway is a validated drug target in cardiovascular disease and an emerging target in Barrett's esophagus, esophageal adenocarcinoma and cancer metastasis.
Description
Thromboxane A2 signaling pathway (GO:0038193) is a biological process in which the lipid mediator thromboxane A2 (TXA2) binds to its cell-surface receptor and triggers intracellular signaling that ultimately regulates downstream cellular responses, including transcription. TXA2 is generated from arachidonic acid through the cyclooxygenase and thromboxane synthase enzymes, and its receptor, TBXA2R, is a G protein-coupled receptor that couples to Gq, Gi and Rho-associated signaling. Because TXA2 is short-lived and acts locally, this pathway is a fast, paracrine and autocrine communication module that coordinates platelet, vascular and immune cell behavior. The pathway is most famous for its role in platelet activation and thrombosis, where it amplifies aggregation and secretion. However, it is also active in endothelial cells, where it attenuates insulin signaling through a Rho-associated kinase/LKB1/PTEN axis, and in the tumor microenvironment, where it promotes cancer progression and metastasis. Recent evidence shows that platelet-derived TXA2 suppresses T cell immunity, and that aspirin prevents metastasis by limiting this suppression. This makes GO:0038193 a high-value target for cardiovascular, metabolic, inflammatory and oncological research. For researchers, GO:0038193 provides a defined ontology anchor for interpreting transcriptomic, proteomic and functional screens involving eicosanoid signaling. It connects lipid metabolism, G protein-coupled receptor biology, cytoskeletal regulation and immune evasion, and it is tractable with CRISPR knockout, point-mutation and knock-in models of TBXA2R, TBXAS1, PTGS1 and PTGS2.
thromboxane A2 signaling pathway At A Glance
| GO ID | GO:0038193 |
|---|---|
| GO term | thromboxane A2 signaling pathway |
| Ontology | biological_process |
| Synonym | TXA(2) receptor signaling; TXA2 signaling |
| Definition | A G protein-coupled receptor signaling pathway initiated by thromboxane A2 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| Major function | Transduces thromboxane A2 signals to regulate platelet activation, vascular tone, secretion, gene expression and immune cell function. |
| Key receptor | TBXA2R (thromboxane A2 receptor), a G protein-coupled receptor. |
| Key enzymes | PTGS1/COX1, PTGS2/COX2 and TBXAS1 (thromboxane synthase) control TXA2 synthesis. |
| Primary ligand | Thromboxane A2 (TXA2), a labile arachidonic acid-derived eicosanoid. |
| Downstream effectors | Gq, Gi, Rho-associated kinase, phosphoinositide-3 kinase and PTEN/LKB1 signaling. |
What Is GO:0038193?
GO:0038193 describes the series of molecular events that begins when thromboxane A2 binds to its receptor on the surface of a target cell and ends with regulation of a downstream cellular process, such as transcription. It is a G protein-coupled receptor signaling pathway, meaning the receptor activates heterotrimeric G proteins that relay the signal to intracellular effectors. The term is synonymous with TXA2 receptor signaling and TXA2 signaling.
Why Is thromboxane A2 signaling pathway Important in Cell Biology?
GO:0038193 is important because thromboxane A2 signaling is a central amplifier of platelet activation and thrombosis, and it also operates in endothelial, immune and tumor cells to shape vascular tone, insulin sensitivity, immune surveillance and metastatic spread. Its receptor and synthetic enzymes are druggable, and aspirin, a widely used COX inhibitor, acts in part by suppressing TXA2 production. Understanding this pathway therefore informs cardiovascular pharmacology, cancer biology and immunotherapy.
• Drives platelet aggregation and secretion, making it a core mechanism in hemostasis and arterial thrombosis.
• Amplifies platelet activation through Gi-coupled phosphoinositide-3 kinase signaling.
• Regulates endothelial insulin signaling via a Rho-associated kinase/LKB1/PTEN pathway, linking TXA2 to metabolic dysfunction.
• Promotes cancer progression and metastasis through thromboxane synthase and receptor signaling.
• Supports Barrett's esophagus and esophageal adenocarcinoma development via COX1/2-driven TXA2 production.
• Suppresses T cell immunity in the tumor microenvironment, and aspirin limits metastasis by blocking this effect.
• Provides a mechanistic explanation for the cardiovascular benefits of low-dose aspirin.
• Is a tractable CRISPR target for dissecting receptor versus synthase contributions in disease models.
What Happens During thromboxane A2 signaling pathway?
Synthesis and release of thromboxane A2
In simple terms: Cells first build the signal molecule TXA2 from arachidonic acid using COX enzymes and thromboxane synthase.
Thromboxane A2 is synthesized from arachidonic acid by cyclooxygenase enzymes (PTGS1/COX1 and PTGS2/COX2) and thromboxane synthase (TBXAS1). Because TXA2 is chemically unstable, it acts locally on nearby cells in a paracrine or autocrine manner. In platelets, TXA2 synthesis is tightly coupled to activation, and a sequence within the cytoplasmic tail of GpIIb can independently activate platelet aggregation and thromboxane synthesis.
Receptor binding and G protein activation
In simple terms: TXA2 docks onto its receptor on the cell surface, which switches on G proteins inside the cell.
The thromboxane A2 receptor (TBXA2R) is a G protein-coupled receptor that binds TXA2 and activates heterotrimeric G proteins, including Gq and Gi. This receptor is the defining entry point of GO:0038193, and its activation initiates downstream signaling cascades. Gi signaling through phosphoinositide-3 kinase potentiates TXA2-induced platelet secretion.
Downstream effector signaling
In simple terms: Activated G proteins turn on enzymes and kinases that change cell behavior.
TBXA2R activation engages Rho-associated kinase and modulates LKB1/PTEN signaling, which can attenuate endothelial insulin signaling. In platelets, Gi-dependent phosphoinositide-3 kinase signaling amplifies secretion. These effector branches convert the initial TXA2 signal into changes in cytoskeleton, metabolism and gene expression.
Cellular responses and transcriptional regulation
In simple terms: The signal ends by changing what the cell does, including switching genes on or off.
The pathway concludes with regulation of downstream cellular processes such as transcription, as stated in the GO definition. In immune and tumor contexts, TXA2 signaling suppresses T cell immunity and promotes cancer progression, indicating durable effects on cell state. In Barrett's esophagus and esophageal adenocarcinoma, COX1/2-driven TXA2 pathway activity supports disease development.
Key Genes Involved in GO:0038193 thromboxane A2 signaling pathway
The following genes and proteins are core components or well-documented modulators of the thromboxane A2 signaling pathway (GO:0038193).
| Gene | Major Role | Research Relevance |
|---|---|---|
| TBXA2R | Thromboxane A2 receptor; G protein-coupled receptor that initiates the pathway | Primary receptor target for knockout, point-mutation and knock-in studies of GO:0038193 |
| TBXAS1 | Thromboxane synthase; converts prostaglandin H2 to thromboxane A2 | Determines ligand availability; knockout reduces TXA2 production |
| PTGS1 | Cyclooxygenase 1; upstream enzyme in TXA2 synthesis | Aspirin target; modulates platelet TXA2 and immune suppression |
| PTGS2 | Cyclooxygenase 2; inducible upstream enzyme in TXA2 synthesis | Inflammation- and cancer-linked source of TXA2 |
| GNAQ | Gq alpha subunit; couples TBXA2R to downstream effectors | Mediates receptor-proximal signaling |
| GNAI1 | Gi alpha subunit; couples TBXA2R to phosphoinositide-3 kinase | Potentiates platelet secretion |
| PIK3CA | Phosphoinositide-3 kinase catalytic subunit | Required for Gi-dependent potentiation of TXA2-induced secretion |
| RHOA | Rho GTPase; activates Rho-associated kinase | Links TBXA2R to endothelial insulin signaling suppression |
| ROCK1 | Rho-associated kinase; downstream effector of TXA2 signaling | Mediates LKB1/PTEN pathway effects on insulin signaling |
| STK11 | LKB1 kinase; modulated by TXA2 receptor signaling | Connects TXA2 to metabolic and growth regulation |
| PTEN | Phosphatase and tensin homolog; modulated by TXA2 receptor signaling | Links TXA2 to phosphoinositide-3 kinase pathway control |
| ITGA2B | Integrin alpha-IIb; platelet aggregation receptor | Cytoplasmic tail sequence independently activates aggregation and TXA2 synthesis |
| ITGB3 | Integrin beta-3; platelet aggregation receptor | Partners with ITGA2B in platelet TXA2 responses |
| CD36 | Scavenger receptor involved in platelet and vascular lipid signaling | Modulates eicosanoid-related platelet function |
| ALOX12 | 12-lipoxygenase; related eicosanoid pathway enzyme | Context for eicosanoid crosstalk in platelets |
| NFKB1 | Transcription factor downstream of inflammatory signaling | Potential transcriptional endpoint of TXA2 signaling |
| STAT3 | Transcription factor linked to tumor progression | Downstream of cancer-associated TXA2 signaling |
| CD8A | T cell co-receptor marking cytotoxic T cells | Platelet TXA2 suppresses T cell immunity; relevant to metastasis studies |
How Is thromboxane A2 signaling pathway Regulated?
Thromboxane A2 signaling is regulated at multiple levels. Ligand availability is controlled by the balance of COX1/COX2 and thromboxane synthase activity, and aspirin or other COX inhibitors reduce TXA2 production. Receptor-proximal signaling is modulated by G protein coupling, with Gi and phosphoinositide-3 kinase potentiating platelet secretion. Downstream, Rho-associated kinase and LKB1/PTEN signaling shape the duration and metabolic consequences of receptor activation. In the tumor microenvironment, platelet-derived TXA2 suppresses T cell immunity, and blocking this axis with aspirin limits metastasis.
thromboxane A2 signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TBXA2R | Thrombosis and platelet hyperreactivity | Platelet-specific knockout or point-mutation knock-in in cell models |
| TBXAS1 | Thromboxane overproduction and vascular disease | Knockout of thromboxane synthase in endothelial or platelet-like cells |
| PTGS1 | Aspirin-sensitive platelet TXA2 and metastasis | COX1 knockout or catalytic point mutation in cancer-platelet co-culture |
| PTGS2 | Inflammation-associated cancer and Barrett's esophagus | Inducible COX2 overexpression or knockout in esophageal cell models |
| CD8A | T cell immunity suppression and metastasis | T cell co-culture with TXA2-producing platelets; CRISPR knockout of TBXA2R in T cells |
Thrombosis and cardiovascular disease
TXA2 is a potent platelet agonist and vasoconstrictor, and GO:0038193 underlies platelet aggregation and secretion that contribute to arterial thrombosis. Aspirin irreversibly inhibits COX enzymes and suppresses TXA2 synthesis, which is a cornerstone of cardiovascular prevention.
Cancer progression and metastasis
Thromboxane synthase and receptor signaling promote cancer progression and metastasis. Platelet TXA2 suppresses T cell immunity, and aspirin prevents metastasis by limiting this suppression, directly linking GO:0038193 to anti-tumor immunity. COX1/2-driven TXA2 pathway activity also supports Barrett's esophagus and esophageal adenocarcinoma development.
Metabolic and endothelial dysfunction
TBXA2R activation engages a Rho-associated kinase/LKB1/PTEN pathway that attenuates endothelium insulin signaling, connecting TXA2 to vascular insulin resistance. This positions GO:0038193 as a mechanistic link between eicosanoid signaling and metabolic disease.
From thromboxane A2 signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TBXA2R mediate TXA2-induced platelet secretion? | TBXA2R knockout platelet-like cell line |
| Which G protein couples TBXA2R to phosphoinositide-3 kinase? | Point-mutation knock-in of GNAI1 or GNAQ in receptor-expressing cells |
| Does thromboxane synthase drive ligand production? | TBXAS1 knockout with TXA2 metabolite measurement |
| Does platelet TXA2 suppress T cell immunity? | Co-culture of PTGS1/TBXAS1 knockout platelets with CD8A T cells |
| Does TBXA2R signaling attenuate endothelial insulin signaling? | Endothelial TBXA2R overexpression or knockout with insulin-response readouts |
| Does COX1/2-driven TXA2 support esophageal adenocarcinoma? | PTGS1/PTGS2 knockout or overexpression in Barrett's esophagus cell models |
How to Study the thromboxane A2 signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA sequencing | Transcriptional changes downstream of TXA2 signaling | Identifying pathway endpoints and disease networks |
| Platelet aggregation assay | Functional platelet activation | Testing TBXA2R and GpIIb contributions |
| Platelet secretion assay | Dense and alpha granule release | Testing Gi/phosphoinositide-3 kinase potentiation |
| Thromboxane B2 ELISA | Stable TXA2 metabolite levels | Assessing COX1/2 and TBXAS1 activity |
| CRISPR knockout | Loss-of-function causality | Testing TBXA2R, TBXAS1, PTGS1 or PTGS2 requirement |
| Immune co-culture | T cell activation and cytotoxicity | Testing platelet TXA2 suppression of immunity |
| Insulin signaling assay | Akt phosphorylation and glucose uptake | Testing endothelial TBXA2R effects |
| Metastasis model | Tumor dissemination in vivo | Testing aspirin and TXA2 pathway blockade |
Transcriptomic and pathway profiling
RNA sequencing of cells with TBXA2R, TBXAS1, PTGS1 or PTGS2 perturbation can identify transcriptional endpoints of GO:0038193, consistent with the GO definition that the pathway ends with regulation of transcription. Pathway enrichment can place TXA2 signaling within inflammatory, thrombotic and cancer gene networks.
Functional platelet and secretion assays
Platelet aggregation and secretion assays are classical readouts for TXA2 signaling, and they can be combined with Gi or phosphoinositide-3 kinase inhibition to dissect coupling. GpIIb cytoplasmic tail mutants have been used to separate aggregation from thromboxane synthesis.
Metabolite and lipid mediator measurement
Because TXA2 is unstable, its stable metabolite thromboxane B2 is commonly measured to infer pathway activity. Such measurements are useful in aspirin studies and in cancer models where COX1/2-driven TXA2 production is relevant.
CRISPR perturbation and immune co-culture
CRISPR knockout of TBXA2R in T cells or of PTGS1/TBXAS1 in platelets enables testing of whether TXA2 signaling cell-autonomously suppresses immunity. Co-culture with tumor cells and metastasis assays can then link molecular changes to phenotype.
How CRISPR Can Be Used to Study GO:0038193 thromboxane A2 signaling pathway
Knockout
CRISPR knockout of TBXA2R, TBXAS1, PTGS1 or PTGS2 provides clean loss-of-function models to test whether GO:0038193 is required for platelet activation, immune suppression or tumor progression. Knockout of TBXA2R in T cells can determine whether TXA2 acts directly on adaptive immunity.
Point Mutation
Point-mutation knock-in can dissect receptor coupling and enzyme catalysis. For example, mutations in G protein contact sites of TBXA2R or in the catalytic residues of TBXAS1 can separate Gq from Gi signaling or synthesis from receptor activation. Such models are valuable because the pathway has multiple effector branches.
Knock-in
Tagged or reporter knock-in of TBXA2R allows visualization of receptor trafficking and surface expression in live cells. Knock-in of disease-associated variants can test whether specific alleles alter TXA2 signaling output in cardiovascular or cancer contexts.
Overexpression
Overexpression of TBXA2R, TBXAS1, PTGS1 or PTGS2 can amplify pathway output and reveal sufficiency in endothelial insulin resistance, platelet secretion or tumor cell proliferation. Overexpression models are particularly useful when endogenous TXA2 levels are low.
How EDITGENE Supports thromboxane A2 signaling pathway Research
Researchers studying thromboxane A2 signaling pathway-related genes often need to determine whether a candidate gene is causally involved in receptor-proximal signaling, ligand synthesis or downstream transcriptional responses. EDITGENE provides publication-ready CRISPR cell models and screening services to test these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for thromboxane A2 signaling pathway research.
Frequently Asked Questions About thromboxane A2 signaling pathway
What is GO:0038193?
GO:0038193 is the Gene Ontology term for thromboxane A2 signaling pathway, a G protein-coupled receptor signaling pathway initiated by thromboxane A2 binding to its receptor and ending with regulation of a downstream cellular process such as transcription.
What is thromboxane A2 signaling pathway?
It is the cellular process in which thromboxane A2, a labile arachidonic acid metabolite, binds the TBXA2R receptor and activates G protein-dependent signaling to control platelet, vascular and immune cell responses.
What genes are involved in thromboxane A2 signaling pathway?
Core genes include TBXA2R, TBXAS1, PTGS1, PTGS2, GNAQ, GNAI1, PIK3CA, RHOA, ROCK1, STK11 and PTEN.
Which receptor mediates thromboxane A2 signaling?
The thromboxane A2 receptor TBXA2R, a G protein-coupled receptor, mediates the pathway.
How is thromboxane A2 synthesized?
Thromboxane A2 is synthesized from arachidonic acid by cyclooxygenase enzymes PTGS1/COX1 and PTGS2/COX2, followed by thromboxane synthase TBXAS1.
Why is thromboxane A2 signaling important in platelets?
It amplifies platelet aggregation and secretion, and Gi signaling through phosphoinositide-3 kinase potentiates TXA2-induced platelet secretion.
How does aspirin affect thromboxane A2 signaling?
Aspirin inhibits cyclooxygenase enzymes and reduces TXA2 synthesis; recent work shows aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity.
Is thromboxane A2 signaling involved in cancer?
Yes, thromboxane synthase and receptor signaling promote cancer progression and metastasis, and COX1/2-driven TXA2 supports esophageal adenocarcinoma development.
What experimental models are used to study GO:0038193?
Common models include TBXA2R, TBXAS1, PTGS1 and PTGS2 knockout or overexpression cells, platelet aggregation and secretion assays, thromboxane B2 measurement and immune co-culture.
How can CRISPR help study thromboxane A2 signaling pathway?
CRISPR knockout, point-mutation knock-in and overexpression models allow causal testing of receptor, enzyme and downstream effector genes in thrombosis, metabolism and cancer.
Conclusion
GO:0038193 thromboxane A2 signaling pathway is a compact but powerful biological process that links lipid metabolism to G protein-coupled receptor signaling, platelet function, vascular biology and immune regulation. Its receptor TBXA2R and synthetic enzymes PTGS1, PTGS2 and TBXAS1 are established drug targets, and emerging evidence connects the pathway to cancer metastasis and immune evasion. For researchers, the pathway offers clear entry points for CRISPR-based causal studies. Knockout, point-mutation, knock-in and overexpression models of TBXA2R and related genes can resolve how TXA2 signals in platelets, endothelium, immune cells and tumors, supporting both mechanistic discovery and therapeutic development.
References
- 1. Yang J et al.. 2025. Aspirin prevents metastasis by limiting platelet TXA(2) suppression of T cell immunity.. Nature 640(8060):1052-1061 PMID: 40044852
- 2. Halushka PV et al.. 1995. Thromboxane A2 receptors.. J Lipid Mediat Cell Signal 12(2-3):361-78 PMID: 8777579
- 3. Song P et al.. 2009. Thromboxane A2 receptor activates a Rho-associated kinase/LKB1/PTEN pathway to attenuate endothelium insulin signaling.. J Biol Chem 284(25):17120-17128 PMID: 19403525
- 4. Ekambaram P et al.. 2011. The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis.. Cancer Metastasis Rev 30(3-4):397-408 PMID: 22037941
- 5. Zhang T et al.. 2019. Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.. EBioMedicine 49:145-156 PMID: 31707149
- 6. Barinov EF. 2016. [Thromboxane A2: Mechanisms of Synthesis and Intracellular Signaling System of Realization].. Kardiologiia 56(4):83-90 PMID: 28294864
- 7. Stephens G et al.. 1998. A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis.. J Biol Chem 273(32):20317-22 PMID: 9685382
- 8. Dangelmaier C et al.. 2001. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway.. Thromb Haemost 85(2):341-8 PMID: 11246558
